China gains importance in global rare disease trials, Fortrea says

• Fortrea’s analysis highlights China’s growing role in global rare disease trials as regulatory reforms enable earlier participation in international development.
• Expanded clinical infrastructure and access to large patient populations strengthen China’s appeal to global trial sponsors.
• Early regulatory engagement and biospecimen planning can reduce startup delays; specialized site selection can support recruitment and study performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortrea Holdings Inc. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.